Neurocrine Biosciences Reports Second Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Tech stocks bolster Wall Street as Nvidia quells AI growth concerns
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil rises by over $1 as White House says no US-Iran talks happening
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Revolution Medicines prices RASONQUE at $39,800 per month
Neurocrine Bio. (NBIX) PT Raised to $145 at Piper Sandler Due to Ingrezza Long-Term Potential
August 4, 2020 9:10 AM EDTPiper Sandler analyst David Amsellem raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $145.00 (from $141.00) while maintaining an Overweight rating, citing Ingrezza sales and volumes, a cinrecerfront Phase III study in CAH patients, an increasingly deep pipeline, and the low rates of TD... More
Neurocrine Biosciences (NBIX) Tops Q2 EPS by 69c, Revenues Beat
August 3, 2020 4:42 PM EDTNeurocrine Biosciences (NASDAQ: NBIX) reported Q2 EPS of $1.42, $0.69 better than the analyst estimate of $0.73. Revenue for the quarter came in at $302.4 million versus the consensus estimate of $260.52 million.
"I want to thank healthcare providers and our employees for the perseverance they showed... More
